Understanding Agammaglobulinemia Type 10 (AGM10)

If you or your child have been diagnosed with Agammaglobulinemia Type 10 (AGM10), you are part of an extremely small global community. This condition is so rare that only a small number of cases and families have been formally identified and reported in the medical literature ^[1][2]. Because it was characterized by scientists in the early 2020s, it is very likely that your local doctor or general practitioner has never encountered it before. This does not mean your care is in the wrong hands, but it does mean that having a specialist clinical immunologist lead your care team is essential for managing such a rare “inborn error of immunity” ^[3].

What is AGM10?

AGM10 is a genetic condition that fundamentally changes how your immune system is built. It is caused by a mutation in a specific gene called SPI1, which provides the instructions for making a protein called PU.1 ^[1].

Think of the PU.1 protein as a “master architect” for your blood cells. Its job is to open up the genetic blueprints that allow your body to create B cells (the white blood cells that produce antibodies) and dendritic cells (cells that act as “scouts” to alert the rest of the immune system to an invader) ^[1][2].

In AGM10, the body often does not produce enough of this architect protein—a state doctors call haploinsufficiency ^[1]. Without enough PU.1, the construction of B cells stops early in the process. As a result, many reported patients have:

• Agammaglobulinemia: A near-total lack of immunoglobulins (antibodies), which are the proteins your body uses to “tag” and neutralize bacteria and viruses ^[2].
• B-cell Lymphopenia: A profound shortage or total absence of B cells in the blood ^[3].
• Dendritic Cell Deficiency: A shortage of “scout” cells, which is a unique feature that helps distinguish AGM10 from other similar conditions ^[4].

Why the Diagnosis Can Be Difficult

It is common for families to face a “diagnostic odyssey”—a long period of confusing tests and frequent infections before finding the answer. AGM10 is often missed because it was not included on older, standard primary immunodeficiency (PID) panels ^[3]. Because AGM10 was discovered so recently, many standard panels simply didn’t have the SPI1 gene on their list of things to check.

If a standard panel comes back negative but the symptoms of missing B cells remain, specialists often turn to broader panels or Whole-Exome Sequencing (WES). This is a broader genetic search that looks at all the protein-coding genes in your DNA, which is how many of the known cases of AGM10 were identified ^[3].

Names You Might Hear

Because different researchers discovered and described this condition around the same time, you may see it referred to by several names in your medical records:

• AGM10: Agammaglobulinemia Type 10.
• PU.MA: PU.1-Mutated Agammaglobulinemia ^[1].
• PU.1 Deficiency: Named after the protein that is missing.
• SPI1-Related Immunodeficiency: Named after the gene that contains the mutation.

Understanding Rarity and Inheritance

Current research indicates that AGM10 is autosomal dominant, meaning a mutation in just one of the two copies of the SPI1 gene is enough to cause the condition ^[2]. A heterozygous parent has a 50% chance of passing the variant on. However, the disease shows variable expressivity and incomplete penetrance ^[2][4]:

• Variable Expressivity: This means that even people with the exact same mutation can have different levels of severity. One person might have a total lack of antibodies from birth, while a relative might only have a mild deficiency that is discovered in adulthood ^[2].
• Incomplete Penetrance: Not everyone with the variant develops clinical symptoms. In a small study of 33 people with the mutation, about 81.8% showed symptoms, while the others appeared unaffected ^[2]. Note that these exact figures come from a small cohort, and your personal probability may vary.

Because of these factors, your immunology team may recommend speaking with a genetic counselor to discuss testing for your parents or siblings ^[4].

Moving Toward Management

While the diagnosis is rare, the management of AGM10 follows well-established paths used for other severe antibody deficiencies. The primary goal is to replace what the body cannot make. This typically involves:

1. Immunoglobulin Replacement Therapy (IgRT): Regular infusions of donor antibodies (given either intravenously or under the skin) to provide the protection your body is missing ^[5][6]. Note that IgRT replaces antibodies, but does not replace dendritic cells.
2. Infection Monitoring: Close surveillance for respiratory and intestinal infections, which are common in this condition ^[5].
3. Specialist Care: Coordination between immunologists and geneticists to monitor your immune health and tailor treatments.

Receiving a diagnosis is the first step toward a treatment plan that can help protect your health and reduce the cycle of infections.